The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

This Phase II, randomized, double-blind, placebo-controlled dose-ranging, parallel and adaptive study aims to evaluate the efficacy and safety of enpatoran in SLE and in CLE (SCLE and/or DLE) participants receiving standard of care (WILLOW). To Learn More Contact: EMD Serono US Medical Information at 888-275-7376 or email at eMediUSA@emdserono.com Communications Center by phone at +49 …

Read More

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

The Phase 3 study will assess atacicept vs. placebo on the impact of renal (kidney) function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period. To Learn More …

Read More

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) (POETYK SLE-2)

The purpose of this Phase 3 study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population. To Learn More Contact: The BMS Study Connect Contact Center at www.BMSStudyConnect.com or call 855-907-3286 or email Clinical.Trials@bms.com. First line of the email must contain …

Read More

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

The purpose of this Phase 3 study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population. To Learn More Contact BMS Study Connect Contact Center www.BMSStudyConnect.com or call 855-907-3286 or email Clinical.Trials@bms.com. First line of the email must contain the NCT …

Read More

A Study to Assess the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

The primary objectives of the study are to evaluate the efficacy of BIIB059 compared with placebo in reducing skin disease activity measured by the Cutaneous Lupus Activity of Physician’s Global Assessment-Revised (CLA-IGA-R) score [Parts A and B (US)] and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score [Part B (ROW)] in …

Read More

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients with Moderately to Severely Active Systemic Lupus Erythematosus

CATEGORIES: General SLE First posted April 1, 2022, Updated July 11, 2022; Recruiting The purpose of this  Phase 3 study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE. To Learn More Contact Call RemeGen at 301-284-1015 or by email to RC18_SLEstudy@remegenbio.com ClinicalTrials.gov identifier (NCT number): NCT05306574 …

Read More

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up